Dr Andrei Egorov | CSO
Vacthera BioTech GmbH

Dr Andrei Egorov, CSO, Vacthera BioTech GmbH

Dr. Andrej Egorov received his MD and PhD in St. Petersburg, Russia.  The initial topic of his carrier was research and development of the live cold-adapted attenuated influenza vaccine. From 1996 he has been working as professor at the Institute of Applied Microbiology in Vienna, Austria. In 1998 he published his key results http://www.ncbi.nlm.nih.gov/pubmed/9658085 describing influenza NS1 protein truncated mutants defective in interferon antagonizing function. Following research http://www.ncbi.nlm.nih.gov/pubmed/9878611;http://www.ncbi.nlm.nih.gov/pubmed/15542655 ; http://www.ncbi.nlm.nih.gov/pubmed/16971432 was addressed to the development of a new generation of live influenza vaccine and vectors with manipulated NS1 gene. From 2006  -  VP Research, Avir Green Hills Biotechnology  AG, Austria.  Since 2012 Egorov is a founder and CSO of an Austrian startup company developing attenuated influenza vaccine vectors.

back to speakers